ARCA Biopharma IncNASDAQ:ABIO
- LAST PRICE3.3550
- TODAY'S CHANGE (%)0.1050 (3.2308%)
- Bid / Lots3.3400/ 4
- Ask / Lots3.3700/ 20
- Open / Previous Close3.2600 / 3.2500
- Day Range
- 52 Week Range
- Volume336,258
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABIO |
|---|---|---|
| 09:32 ET | 191 | 3.26 |
| 09:48 ET | 556 | 3.21 |
| 09:50 ET | 4991 | 3.3489 |
| 09:52 ET | 100 | 3.33 |
| 09:56 ET | 1079 | 3.3404 |
| 09:57 ET | 22325 | 3.3995 |
| 09:59 ET | 14637 | 3.4072 |
| 10:03 ET | 2920 | 3.37 |
| 10:06 ET | 2300 | 3.3701 |
| 10:08 ET | 20100 | 3.4 |
| 10:10 ET | 3096 | 3.3685 |
| 10:12 ET | 1324 | 3.405 |
| 10:14 ET | 974 | 3.4049 |
| 10:17 ET | 2000 | 3.3599 |
| 10:19 ET | 940 | 3.4 |
| 10:21 ET | 900 | 3.4 |
| 10:28 ET | 100 | 3.3676 |
| 10:32 ET | 800 | 3.4 |
| 10:33 ET | 40600 | 3.385 |
| 10:35 ET | 85200 | 3.385 |
| 10:37 ET | 22598 | 3.385 |
| 10:39 ET | 10750 | 3.3891 |
| 10:42 ET | 8880 | 3.39 |
| 10:44 ET | 9520 | 3.4 |
| 10:46 ET | 16778 | 3.405 |
| 10:48 ET | 1200 | 3.405 |
| 10:50 ET | 3277 | 3.4052 |
| 10:51 ET | 2080 | 3.4098 |
| 10:53 ET | 200 | 3.4095 |
| 10:55 ET | 6965 | 3.3965 |
| 10:57 ET | 14900 | 3.39 |
| 11:09 ET | 8500 | 3.41 |
| 11:11 ET | 1075 | 3.41 |
| 11:13 ET | 100 | 3.405 |
| 11:15 ET | 2489 | 3.4 |
| 11:18 ET | 1188 | 3.41 |
| 11:20 ET | 100 | 3.4012 |
| 11:22 ET | 1234 | 3.4 |
| 11:26 ET | 2775 | 3.42 |
| 11:27 ET | 200 | 3.3697 |
| 11:29 ET | 100 | 3.4 |
| 11:31 ET | 100 | 3.385 |
| 11:33 ET | 1100 | 3.385 |
| 11:36 ET | 100 | 3.385 |
| 11:40 ET | 100 | 3.39 |
| 11:42 ET | 1100 | 3.39 |
| 11:44 ET | 7670 | 3.3554 |
| 11:45 ET | 100 | 3.3635 |
| 11:49 ET | 2000 | 3.35 |
| 11:51 ET | 700 | 3.355 |
| 11:54 ET | 200 | 3.355 |
Apr 15, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, ABIO, MODN, from 8:38AM ET on Monday Apr 15, 2024 by Dow Jones
8:38AM ET on Monday Apr 15, 2024 by Dow JonesBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc. (Nasdaq -- SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE -- MODN), ARCA biopharma, Inc. (Nasdaq - ABIO), from 8:03AM ET on Monday Apr 15, 2024 by Dow Jones
8:03AM ET on Monday Apr 15, 2024 by Dow Jones
Apr 10, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANSS, HRT, CHX, ABIO, from 2:04PM ET on Wednesday Apr 10, 2024 by Dow Jones
2:04PM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 9, 2024
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO, from 8:10PM ET on Tuesday Apr 09, 2024 by Dow Jones
8:10PM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 8, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, MODN, ABIO, from 2:25PM ET on Monday Apr 08, 2024 by Dow Jones
2:25PM ET on Monday Apr 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ARCA Biopharma Inc | 47.1M | -9.1x | --- |
Quince Therapeutics Inc | 45.8M | -1.3x | --- |
Apollomics Inc | 45.6M | -9.3x | --- |
IN8BIO, Inc. | 45.5M | -1.0x | --- |
Eledon Pharmaceuticals Inc | 49.4M | -1.1x | --- |
Xilio Therapeutics Inc | 44.1M | -0.4x | --- |
Company Information
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.
Contact Information
- Headquarters
- 10170 Church Ranch Way, Suite 100WESTMINSTER, CO, United States 80021
- Phone
- 720-940-2200
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Robert Conway
- President, Principal Executive Officer, Chief Operating Officer
- Thomas Keuer
- Chief Financial Officer
- C. Jeffrey Dekker
- Director
- James Flynn
- Independent Director
- Linda Grais
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-0.37 |
Book Value | $2.55 |
P/E Ratio | -9.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
